• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagnetic Semiconductor Architecture

    5/19/26 8:17:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HOTH alert in real time by email

    Company Targets Power Demands of AI Data Centers Through Patented Nanomagnetic Semiconductor and Spintronic Computing Technologies for AI, Defense, and Space Applications

    HOBOKEN, N.J., May 19, 2026 /PRNewswire/ -- (NASDAQ:HOTH) ("Hoth" or the "Company") today announced that it intends to change its name to Rocket One, Inc. ("Rocket One"), and to restructure its business to position the Company, through its recently formed wholly-owned subsidiary, to pursue opportunities in artificial intelligence infrastructure, next-generation semiconductor technologies, and ultra-low-power AI computing.

    (PRNewsfoto/Hoth Therapeutics Inc.)

    Under its soon to be newly rebranded name, Rocket One, Inc., and the newly obtained licenses, the Company will enter the expanding AI semiconductor market, with exclusive rights to AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagnetic Semiconductor Architecture and to spintronic computing technologies developed at Virginia Commonwealth University ("VCU") targeting one of the largest challenges facing artificial intelligence today: power consumption and computing efficiency.

    The Company intends to continue its biotechnology programs and is exploring placing its biotechnology assets in a separate, wholly owned subsidiary.

    The refocusing of the business was unanimously approved by the Company's Board of Directors. Additional details regarding the licenses and proposed business will be included in a Current Report on Form 8-K that will be filed timely with the Securities and Exchange Commission.

    AI Infrastructure Is Reaching a Breaking Point

    Artificial intelligence has become the defining workload of modern computing, driving an unprecedented global buildout of AI data centers, autonomous systems, edge AI infrastructure, and high-performance computing environments.

    But the AI industry is increasingly constrained by:

    • escalating power consumption
    • cooling limitations
    • memory bottlenecks
    • inference latency
    • rising infrastructure costs

    As demand for large language models, generative AI, and autonomous systems accelerates globally, the world's largest technology companies are actively searching for next-generation semiconductor architectures capable of delivering dramatically improved efficiency beyond conventional silicon approaches.

    The Company believes solving these infrastructure constraints represents one of the most significant opportunities in the future of artificial intelligence.

    Exclusive AI Semiconductor and Spintronic Computing Portfolio

    Rocket One has secured exclusive rights to what it believes are two complementary spintronic semiconductor technologies. And

    Nanomagnetic Matrix Multiplier — AI Hardware Acceleration

    The Company secured exclusive rights to 

    "A compact, low-energy, non-volatile nanomagnetic matrix multiplier as a hardware accelerator for machine learning and artificial intelligence."

    Matrix multiplication is the foundational operation underlying virtually all modern AI workloads, including transformer architectures powering large language models and generative artificial intelligence systems.

    The licensed architecture is designed to support:

    • ultra-low-power AI acceleration
    • next-generation AI inference
    • advanced memory efficiency
    • edge AI systems
    • intelligent autonomous platforms
    • distributed AI infrastructure

    The second technology utilizes electron spin rather than conventional charge-based semiconductor approaches and is intended to address growing energy efficiency constraints in AI computing infrastructure.

    Spintronic Memory Platform — Defense, Autonomous Systems, and Space Computing

    Rocket One secured exclusive rights to spintronic memory technologies designed for advanced computing and information processing applications with potential relevance to:

    • radiation-tolerant computing
    • defense infrastructure
    • autonomous aerospace systems
    • resilient edge compute
    • orbital AI environments
    • next-generation intelligent systems

    The Company believes the same underlying spintronic physics supporting AI acceleration may also provide long-term opportunities across defense and space-based computing infrastructure markets.

    Building an AI Infrastructure Platform

    The Company intends to pursue a capital-efficient growth strategy focused on:

    • semiconductor infrastructure partnerships
    • AI hardware commercialization
    • sponsored research
    • strategic acquisitions
    • defense and aerospace opportunities
    • advanced compute infrastructure
    • intelligent edge systems

    The Company also plans to expand leadership with expertise spanning:

    • semiconductor operations
    • AI infrastructure
    • advanced computing architectures
    • defense technologies
    • high-performance computing

    Management Commentary

    "Artificial intelligence is rapidly transforming every major industry, but the infrastructure powering AI is approaching critical energy and efficiency limits," said Robb Knie, Chief Executive Officer.

    "We believe next-generation semiconductor architectures capable of dramatically improving power efficiency, memory performance, and intelligent computing scalability represent one of the largest opportunities in global technology today. Rocket One is being built to position the Company to participate in the future of AI infrastructure."

    Biotechnology Operations Continue Under Subsidiary Structure

    The Company 's is exploring placing its biotechnology pipeline and therapeutic development programs under a separate, wholly owned subsidiary with dedicated management and operational resources. The restructuring is intended to preserve the value of the biotechnology portfolio for shareholders while enabling the parent company to pursue emerging opportunities in AI semiconductor infrastructure and advanced computing technologies.

    About Rocket One, Inc.

    Rocket One Inc. is focused on the development and commercialization of spintronic computing technologies for artificial intelligence hardware acceleration and radiation-tolerant computing applications. The Company holds exclusive rights to technologies licensed for nanomagnetic matrix multiplier architecture designed as a hardware accelerator for machine learning and artificial intelligence workloads, and a skyrmion-based spintronic memory technology with potential applications in radiation-tolerant computing for defense and space systems.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the Company's corporate restructuring, strategic direction, the development potential of the licensed technologies, anticipated future operations, planned hires, planned acquisitions, planned research relationships, and the market opportunities described herein. These forward-looking statements are based on the Company's current expectations and assumptions and are subject to numerous risks and uncertainties. Risks include, without limitation: the early-stage nature of the licensed technologies and the absence of any commercial product; the substantial additional capital the Company will require to execute its strategic plan; the Company's ability to raise such capital on acceptable terms or at all; competition from larger and better-funded companies in the semiconductor, AI hardware, and defense computing sectors; the Company's ability to recruit and retain qualified leadership and technical personnel; the Company's ability to identify, finance, and complete strategic acquisitions on acceptable terms; the Company's ability to comply with diligence milestones under the VCU license agreements, the failure of which could result in loss of license rights; intellectual property risks, including that one of the licensed patents is a patent application that has not yet issued and may issue, if at all, with claims narrower than currently sought; government use rights and other limitations on the licensed technologies arising from federal research funding under the Bayh-Dole Act; uncertainties in the demand for spintronic computing solutions; the risks of operating in a regulated industry; and the risks inherent in a corporate restructuring, including those affecting the Company's existing biotechnology operations and shareholder base.

    Additional risk factors are described in the Company's filings with the Securities and Exchange Commission, including the Form 8-K filed concurrently with this press release and the Company's most recent Annual Report on Form 10-K and subsequent quarterly reports. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update such statements except as required by law.

    Investor Contact:

    LR Advisors LLC

    Email: investorrelations@hoththerapeutics.com

    www.hoththerapeutics.com

    Phone: (678) 570-6791

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-chip-energy-efficiency-hoth-therapeutics-restructures-as-rocket-one-inc-to-enter-the-ai-semiconductor-infrastructure-market-with-acquisition-of-exclusive-rights-to-next-generation-ai-semiconductor-acceleration-technology-buil-302776054.html

    SOURCE Hoth Therapeutics, Inc.

    Get the next $HOTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HOTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HOTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense Applications

    Company Adopts Space-Focused Identity, New Ticker "RKTO," and Exclusive License of AI Chip Architecture Designed for Ultra-Low-Power, Radiation-Tolerant Computing in Space and Defense ApplicationsHOBOKEN, N.J., May 27, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("Hoth" or the "Company") today announced that, following the strategic repositioning disclosed on May 19, 2026, it has completed the legal change of its corporate name to Rocket One Inc. ("Rocket One") effective as of May 26, 2026 and will begin trading on The Nasdaq Capital Market under the new ticker symbol "RKTO" at the open of trading on May 28, 2026. The Company's common stock will cease trading under the symbol

    5/27/26 8:11:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform

    Allowed Claims Cover Composition-of-Matter and Methods Targeting MS4A6A Pre-mRNA Splicing to Reduce Surface Expression of the High-Affinity IgE Receptor (FcεRI); Strengthens Intellectual Property Foundation Underlying the HT-KIT Mast Cell ProgramHOBOKEN, N.J., May 26, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("Hoth" or the "Company"), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for Hoth's HT-KIT therapeutic. The allowed claims cover antisense oligomers of 25 to

    5/26/26 8:18:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagnetic Semiconductor Architecture

    Company Targets Power Demands of AI Data Centers Through Patented Nanomagnetic Semiconductor and Spintronic Computing Technologies for AI, Defense, and Space ApplicationsHOBOKEN, N.J., May 19, 2026 /PRNewswire/ -- (NASDAQ:HOTH) ("Hoth" or the "Company") today announced that it intends to change its name to Rocket One, Inc. ("Rocket One"), and to restructure its business to position the Company, through its recently formed wholly-owned subsidiary, to pursue opportunities in artificial intelligence infrastructure, next-generation semiconductor technologies, and ultra-low-power AI computing.

    5/19/26 8:17:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    SEC Filings

    View All

    Hoth Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Rocket One Inc. (0001711786) (Filer)

    6/3/26 8:27:22 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hoth Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Rocket One Inc. (0001711786) (Filer)

    6/3/26 8:26:22 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Hoth Therapeutics Inc.

    424B5 - Rocket One Inc. (0001711786) (Filer)

    6/3/26 8:25:17 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Linsley Wayne

    4 - Rocket One Inc. (0001711786) (Issuer)

    5/28/26 4:16:25 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO and President Knie Robb

    4 - Rocket One Inc. (0001711786) (Issuer)

    5/28/26 4:15:59 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Sarnoff David

    4 - Rocket One Inc. (0001711786) (Issuer)

    5/28/26 4:15:42 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Knie Robb bought $16,750 worth of shares (25,000 units at $0.67), increasing direct ownership by 75% to 58,131 units (SEC Form 4)

    4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

    8/19/24 8:00:03 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    Leadership Updates

    Live Leadership Updates

    View All

    Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

    Company Expands IP Portfolio While Advancing Clinical Innovation in Oncology Supportive Care Case Study and Interim Clinical Trial Results Will Be Discussed NEW YORK, June 5, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company pioneering breakthrough therapies to improve the lives of patients, today announced a Key Opinion Leader (KOL) event showcasing HT-001, its novel topical therapeutic, designed to treat debilitating skin toxicities caused by EGFR inhibitor cancer therapies. These common treatment-limiting side effects—suc

    6/5/25 8:12:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hoth Therapeutics Announces the Appointment of John Cirrito, PhD and Carla Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory Board

    NEW YORK, Jan. 31, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory Board. While serving on the Board, Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ, an oral therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of Alzheimer's disease (AD) and symptoms associated with AD. Mr. Robb Knie, CEO of Hoth Therapeutics, commented, "Hoth is extremely pleased to welcome Dr. Cir

    1/31/22 8:17:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Hoth Therapeutics Inc. (Amendment)

    SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)

    2/14/24 2:47:32 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Hoth Therapeutics Inc.

    SC 13G - Hoth Therapeutics, Inc. (0001711786) (Subject)

    2/14/23 12:55:35 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Hoth Therapeutics Inc. (Amendment)

    SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)

    2/8/23 6:07:04 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care